J Fr

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

- -

TAKANORI TABUCHI ET AL

Serial No. 10/522,798

In re application of

Office of Initial Patent

Filed: February 28, 2005 : Examination's Filing Receipt

Corrections

Title: Novel process for producing imidazo[1,2-b]

pyridazine derivative

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Enclosed herewith is a copy of the Official Filing Receipt for the above-identified application marked in red indicating corrections to be made thereto.

Accordingly, it is requested that the PTO issue a Corrected Filing Receipt reflecting these corrections.

Respectfully submitted,

TAKANORI TABUCHI ET AL

By

Warren M. Cheek

Registration No. 33,367

Attorney for Applicants

/eak

WENDEROTH, LIND & PONACK, L.L.P.

2033 K. St., N.W., Suite 800 Washington, D.C. 20006-1021

Telephone (202) 721-8200

April 22, 2005



United States Patent and

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

FILING OR 371 APPL NO. ART UNIT FIL FEE REC'D ATTY.DOCKET NO DRAWINGS TOT CLMS IND CLMS (c) DATE 10/522,798 02/28/2005 1642 1130 2005 0058A 12 3

CONFIRMATION NO. 6787

FILING RECEIPT

OC000000015689164*

000513 WENDEROTH, LIND & PONACK, L.L.P. 2033 K STREET N. W. SUITE 800 WASHINGTON, DC 20006-1021

Date Mailed: 04/15/2005

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s).

Takanori Tabuchi, Osaka-shi, JAPAN; Tetsuhiro Yamamoto, Nishinomiya-shi, JAPAN; Takeshi Kajiwara, Niiharigun, JAPAN;

Power of Attorney: The patent practitioners associated with Customer Number 000513.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP03/09003 07/16/2003

Foreign Applications

JAPAN 2002-219786 07/29/2002 TAPAN / 100244 JAN, 15, 2003 JAPAN 2003-85617 03/26/2003

Projected Publication Date: To Be Determined - pending completion of Security Review

Non-Publication Request: No

Early Publication Request: No

Title



Novel process for producting imidazo[1,2-b]pyridazine derivative

Preliminary Class

435

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).